Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retifanlimab with Bevacizumab and HFRT in Recurrent GBM
NCT06160206Phase 2Recruiting
- Sponsor
- Academic and Community Cancer Research United
- Start
- Oct 2024
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of retifanlimab in glioblastoma (GBM), sponsored by Academic and Community Cancer Research United. Started Oct 2024; status: recruiting.
02
Drugs
retifanlimab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06160206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06160206.